-
Novavax, Inc. (NVAX) shares surged 98.7% after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu vaccine.
-
Moderna, Inc. (MRNA) shares dropped 4.4% after the company announced that the Food and Drug Administration (FDA) postponed its approval decision for Moderna’s respiratory syncytial virus (RSV) vaccine.
-
Shares of Genpact Limited (G) rose 3.6% after reporting first-quarter 2024 revenues of $1.13 billion, outpacing the Zacks Consensus Estimate of $1.11 billion.
-
IAMGOLD Corporation (IAG) shares increased 11.7% after reporting first-quarter 2024 adjusted earnings per share of $0.11, exceeding the Zacks Consensus Estimate of $0.2 per share.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
Genpact Limited (G) : Free Stock Analysis Report
Novavax, Inc. (NVAX) : Free Stock Analysis Report
Iamgold Corporation (IAG) : Free Stock Analysis Report